Based on the molecular docking results, the top 9 compounds unraveled higher binding affinities than that of alisertib (MLN8237, Milennium Pharmaceuticals, Inc., Cambridge, MA), which is a highly selective AURKA small-molecule inhibitor developed for the treatment of malignancies [37, 38] (Table 1). Here, AURKA is linked to cancer.